Alterity Therapeutics Limited (NASDAQ:ATHE) Short Interest Update

Alterity Therapeutics Limited (NASDAQ:ATHE) saw a large increase in short interest during the month of June. As of June 15th, there was short interest totalling 22,500 shares, an increase of 8.2% from the May 31st total of 20,800 shares. Based on an average trading volume of 73,900 shares, the short-interest ratio is currently 0.3 days. Approximately 0.3% of the company’s stock are sold short.

Alterity Therapeutics Trading Down 1.1 %

NASDAQ:ATHE traded down $0.02 during trading hours on Tuesday, reaching $1.78. The company had a trading volume of 3,139 shares, compared to its average volume of 57,645. Alterity Therapeutics has a 52 week low of $1.55 and a 52 week high of $5.41. The firm’s 50 day moving average price is $1.97 and its 200-day moving average price is $2.03.

Wall Street Analysts Forecast Growth

Separately, Benchmark reaffirmed a “speculative buy” rating and issued a $4.00 target price on shares of Alterity Therapeutics in a research report on Thursday, March 7th.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease.